甲索特雷克萨特和利图西马布在高度复发的异常性小结节下结节狭窄症中的使用
Andrew S Awadallah1, Andrew J Bowen2, Hawa M Ali3
1Alix School of Medicine, Mayo Clinic, Rochester, Minnesota, U.S.A.
The Laryngoscope
|August 14, 2024
概括
甲索特雷克萨特 (MTX) 和利图西马布 (RTX) 显示出治疗复发性异常性亚结节狭窄症 (iSGS) 的潜力. 虽然在统计学上不显著,但药物治疗趋向于更长的缓解间隔,这表明需要进一步研究.
科学领域:
- 耳鼻喉科 耳鼻喉科 耳鼻喉科
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 异常性小结节狭窄症 (iSGS) 是一种罕见的疾病,其特征是气道狭窄.
- 高度重复的iSGS带来了重大管理挑战,通常需要重复的手术干预.
- 免疫抑制疗法在管理iSGS中的作用,特别是在cANCA阴性患者中,仍在研究中.
研究的目的:
- 评估在患有高复发性iSGS和负canca标位的患者中甲醇 (MTX) 和修复剂 (RTX) 的疗效.
- 评估这些疗法对复发间隔和手术干预需要的影响.
主要方法:
- 对21名高复发性iSGS的女性患者进行了回顾性队列研究.
- 患者接受MTX,RTX或组合治疗 (MTX/RTX).
- 分析了药物治疗前后的手术持续时间和复发间隔.
主要成果:
- 在免疫抑制剂治疗中观察到,手术间隔较长的趋势 (平均药前:338天;药后:697天).
- 三名患者在治疗后实现了缓解,随访时间中位数为1265天.
- 患有先前延期的患者显示药物后复发间隔显著更长 (平均978天).
- 报告的最常见的副作用是恶心 (16%).
结论:
- 甲托雷克萨特和利图西马布可能代表选择性治疗选择,选择患者的高度复发的iSGS.
- 目前的数据表明,最初的反应是可变的,这强调了对最佳患者选择和治疗方案进行进一步调查的必要性.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
01:26Tonsillitis II: Management
105
This lesson will focus on the different treatment options for managing tonsillitis, which typically depend on the cause and severity.
105
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
103
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
103
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
120
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
120
01:23Chronic Pharyngitis
1.5K
Chronic pharyngitis refers to persistent inflammation of the pharyngial mucosa.
Etiology
It often arises from persistent viral or bacterial infections affecting sinuses and tonsils.
Additional contributing factors include inadequate dental hygiene, mouth breathing, recurring tonsillitis, allergic rhinitis, laryngopharyngeal reflux, and exposure to smoke, chemicals, and other environmental pollutants. Allergic reactions to pollen, mold, and pet dander, chronic cough, excessive voice usage,...
Etiology
It often arises from persistent viral or bacterial infections affecting sinuses and tonsils.
Additional contributing factors include inadequate dental hygiene, mouth breathing, recurring tonsillitis, allergic rhinitis, laryngopharyngeal reflux, and exposure to smoke, chemicals, and other environmental pollutants. Allergic reactions to pollen, mold, and pet dander, chronic cough, excessive voice usage,...
1.5K
01:27Pneumothorax-II
127
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
Clinical Manifestations:
127